Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
International Journal of Clinical Oncology|September 9, 2014
Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancerKeisuke Shigeta, Takeo Kosaka, Satoshi Yazawa, et al.
European Journal of Radiology|January 23, 2022
Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examinationYuki Arita, Soichiro Yoshida, Thomas C Kwee, et al.
Abdominal Radiology (New York)|June 7, 2024
Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfallsYuki Arita, Sungmin Woo, Lisa Ruby, et al.
Cell Death Discovery|August 8, 2025
Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cellsNaoki Haratake, Shinkichi Takamori, Hideko Isozaki, et al.
Biomedicines|July 27, 2024
MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare CancerHiroki Ozawa, Naoki Haratake, Ayako Nakashoji, et al.
Oncogene|May 27, 2024
MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progressionAtrayee Bhattacharya, Keyi Wang, Johany Penailillo, et al.
Japanese Journal of Clinical Oncology|September 7, 2020
Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancerKyohei Hakozaki, Eiji Kikuchi, Koichiro Ogihara, et al.
World Journal of Urology|March 26, 2024
Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinomaKazunori Shojo, Toshikazu Takeda, Hirotaka Akita, et al.
European Urology Oncology|August 6, 2022
Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant HistologyYuki Arita, Soichiro Yoshida, Keisuke Shigeta, et al.
Urologic Oncology|March 7, 2020
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patientsKoichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta, et al.
Pageof 6